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Dear Editor,
The COVID-19 pandemic outbreak has raised novel medi-
cal challenges and several unsolved issues. The present case 
draws attention to two major problems: clotting alterations 
in the SARS-CoV-2 infection and the reliability of currently 
available diagnostic tests.
At the end of February 2020, returning from a trip to his 
native Burkina Faso (01/2020), a 64 year old man started to 
suffer from moderate fatigue, not impacting on daily life, and 
abdominal discomfort. He denied fever, cough, dyspnoea, 
diarrhoea or contacts with known cases of COVID-19 over 
the previous 3 months. History was unremarkable, except 
for poorly controlled type-2 diabetes on metformin (HbA1c 
74 mmol/mol, 8.9%) and a 1 cm liver mass, previously iden-
tified as a lipoma and on radiological follow-up.
After a negative first level work-up, the General Prac-
titioner requested a contrast-enhanced abdominal Com-
puterized Tomography (CT), which showed no changes of 
the liver mass. However, as the upper scans revealed sub-
segmental embolism of the lower left lung, the patient was 
referred to the Emergency Department.
On admission, pulse was 90 bpm regular, blood pressure 
165/90 mmHg, respiration rate 20 per minute, and body 
temperature 36 °C. The patient was eupnoeic at rest with 
oxygen saturation 96% breathing ambient air. Physical exam-
ination only unrevealed bilateral basal crackles. First-line 
laboratory findings showed normal full blood count (FBC), 
renal and liver function, and increased D-Dimer (2022 µg/
ml, n.v. < 500 µg/ml) (Table 1). A chest CT-scan identified 
sub-segmental thrombosis in the apical segment of the left 
inferior lobe and the lateral sub-segment of the right medium 
lobe. It also showed diffuse sub pleural ground-glass inter-
stitial involvement, especially in the areas, where throm-
bosis was detected (Fig. 1). Low molecular weight heparin 
(LMWH) was started at anti-coagulant dosage.
According to the local COVID-19 protocol the following 
procedures were performed:
• 6-min Walking Test (6-MWT), showing desaturation 
(89%, > 4% from rest);
• Nasopharyngeal (NF) swab: negative for the presence of 
COVID-19.
Despite the negative swab result, the CT-scan and 
6-MWT findings led us to consider the patient as highly 
suspicious for SARS-CoV-2 infection. According to the 
diagnostic algorithm of the Italian Society of Emergency 
Medicine (SIMEU) the patient was classified at low mor-
tality risk and admitted to the COVID-19 “grey-line” low 
intensity unit for such cases.
The patient was subjected to droplet and contact isolation 
and, 24 h later, a second NF-swab was again negative. To 
further rule out SARS-CoV-2 infection, a bronchoalveolar 
lavage was performed, which also turned negative for SARS-
CoV-2, A/B influenza and respiratory syncytial viruses.
An Eco Doppler scan of the lower limbs did not reveal 
deep vein thrombosis. Therefore, potential prothrombotic 
conditions were considered:
• Abdomen and chest CTs were negative for solid neo-
plasms and venous thrombosis;
• Prostatic Serum Antigen levels were normal;
• FBC was normal;
• Screening for thrombophilia revealed normal levels 
of C protein, S protein, activated protein-C resistance, 
antiphospholipid antibodies (lupus anti-coagulant anti-
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cardiolipin and ß2-microglobulin), factor V Leiden, and 
factor II variants;
• Serum protein electrophoresis showed a non-specific γ 
globulin increase.
• Then, 2  days before dismissal, a qualitative assay 
revealed the presence of SARS-CoV-2 IgG in the serum, 
suggesting COVID-19.
The patient was discharged at home with a diagnosis of 
SARS-CoV-2 related interstitial pneumonia and sub-seg-
mental pulmonary thromboembolism with a prescription 
for direct oral anticoagulants and no specific therapy for 
SARS-CoV-2.
Two discrete COVID-19-associated clotting alterations 
are known: low grade disseminated intravascular coagulation 
and thrombotic microangiopathy, especially localized to the 
lung [1]. These abnormalities have been linked to increased 
circulating levels of pro-inflammatory cytokines (particu-
larly IL-1, TNF-α and IL-6) and endothelial damage. Clini-
cally, the most relevant alterations associated with clotting 
abnormalities in COVID-19 patients are mild thrombocy-
topenia, prolongation of the PT segment, and increased 
D-Dimer, which is considered an important negative prog-
nostic factor. Zhou et al. [2] reported an 18-fold higher risk 
of death in patients with D-Dimer greater than 1000 µg/ml 
on admission and Thachil et al. [3] suggested hospitaliza-
tion for all patients with D-Dimer 3–4 times over the nor-
mal range, even in the absence of severe symptoms. In our 
patient, the most likely mechanism supporting sub-segmen-
tal thromboembolism was SARS-CoV-2 -related thrombotic 
microangiopathy.
This leads to a number of questions. Should the differen-
tial diagnosis of otherwise, unexplained incidental thrombo-
embolism include the active search for SARS-CoV-2 infec-
tion? Should we continue searching for markers of infection 
even in patients with thrombosis without clear SARS-CoV-2 
associated clinical symptoms or pulmonary signature? Will 
testing for SARS-CoV-2 infection become part of routine 
screening for prothrombotic conditions even after the current 
pandemic era will be hopefully over?
The latter question leads to the second issue: how to 
detect the infection? Currently, physicians face two hurdles: 
asymptomatic patients who elude controls, remaining a res-
ervoir for infection, and symptomatic ones in whom search 
for the virus is persistently negative. We know very little 
about the sensitivity and specificity of available diagnostic 
tests and even less about their clinical relevance. In addi-
tion, their reliability depends on operator accuracy and time 
of sampling. For example, NF-swabs are reported to turn 
positive 7–10 days after the onset of symptoms, while bron-
choalveolar lavage (BAL) does so after 3 weeks. In addi-
tion, although RT-PCR is widely used to identify COVID-19 
patients, no viral load threshold has been correlated to infec-
tiousness [4]. NF-swab and BAL false negatives are a com-
monly experience and represent a problem for clinicians [5]
This report suggests that, in suspicious cases, clinical 
judgment based upon biochemical and radiological find-
ings remains a cornerstone in the diagnosis of SARS-CoV-2 
infection. However, since infections and, in general, inflam-
matory diseases are well-known triggers of thrombosis, in 
the presence of typical laboratory or radiologic findings such 
as ground-glass lesions at CT-scan, SARS-CoV-2 infection 
should be carefully ruled out.
Table 1  Patient ‘s biochemical data on admission
WBC white blood cells, LNF lymphocytes, N neutrophils, RBC red 
blood cells, Hb hemoglobin, PLTS platelets, CPR C-reactive protein, 
PCT procalcitonin, INR International normalized ratio, aPTT ratio 
activated partial thromplastin time ratio, AST aspartate transaminase, 
ALT alanine transaminase, CK creatin kinase, LDH lactate dehydro-
genase, NT-Pro-BNP N-terminal fragment-prohormone brain natriu-
retic peptide 
WBC *109 /L 6.10
LNF*106 /L (%) 1750 (28.7%)
N  106 /L (%) 3810 (62.5%)
RBC*  1012 /L 4.84
Hb g/dl 15.3

















Pancreatic Amilase UI/L 9
Na+ mmol/L 138
K+ mmol/L 4.5
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Fig. 1  Patient’s chest CT-scans. The left scans show sub-segmental thromboembolism (red arrows), localized in inferior right lobe (upper scan) 
and medium right lobe (lower scan). The right scans show the ground-glass opacities localized in the same areas
